FDA advisers weigh benefits of weekly insulin diabetes patients [Video]

Most types of insulin therapy, an important part of diabetes treatment for many people, are given as daily injections to help manage blood sugar levels. Now, the maker of a once-weekly insulin injection is seeking approval from the U.S. Food and Drug Administration, but a committee of agency advisers is divided on whether the benefits of the product may outweigh the risks.Related video above: High cost makes weight loss, diabetes drugs inaccessibleIn a meeting Friday, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee weighed whether the benefits of Novo Nordisk’s weekly product, called insulin icodec, outweigh its risks. If the agency signs off, the treatment will be the first weekly insulin available in the United States.The committee’s discussions focused on the safety and efficacy of insulin icodec, specifically in people with type 1 diabetes. The advisers were asked to answer a question of, based on the available data, whether Novo …